Skip to main content

Table 4 Univariate analysis of overall survival according to the VEGF and VEGFR immunohistochemical score in GBMs

From: The immunohistochemical landscape of the VEGF family and its receptors in glioblastomas

  N = 70 Staining score
HR (CI 95%)
Total Stained/Lost (Lost %) Total Positive
N (%)
Absent (−) Focal (+) Intermediate (++) Diffuse (+++)
VEGF-A 62 / 8 (11.4%)a 57/62 (91.9%) 1
5 (7.1%)
0.96 (0.29–3.20)
8 (11.4%)
0.78 (0.26–2.32)
20 (28.6%)
0.86 (0.30–2.47)
29 (41.4%)
VEGF-C 56 /14 (20%)a 53/56 (94.6) 1
3 (4.3%)
1.149 (0.35–6.34)
5 (7.1%)
1.19 (0.31–4.59)
9 (12.9%)
1.11 (0.34–3.63)
39 (55.7%)
VEGF-D 63 /7 (10.0%)a 55/63 (87.3) 1
8 (11.4%)
4.27 (1.30–13.95)
6 (8.6%)
1.45 (0.52–4.06)
11 (15.7%)
1.07 (0.45–2.57)
38 (54.3%)
VEGF-R1 66/4 (5.7%)a 65/66 (98.5) 1
1 (1.4%)
2.14 (0.27–16.98)
10 (14.3%)
1.33 (0.18–10.0)
23 (32.9%)
0.94 (0.13–6.96)
32 (45.7%)
VEGF-R2 64/6 (8.6%)a 63/64 (98.4) 1
1 (1.4%)
1.04 (0.13–8.61)
7 (10.0%)
1.24 (0.16–9.94)
10 (14.3%)
1.29 (0.18–9.42)
46 (65.7%)
VEGF-R3 50/20 (28.6%)a 49/50 (98.0) 1
1 (1.4%)
0.81 (0.07–9.01)
3 (4.3%)
1.27 (0.17–9.56)
20 (28.6%)
1.07 (0.14–8.03)
26 (37.1%)
  1. a Percentage of missing TMA cases